Why Am I Confident (although still anxious)
eIND and Open Label Extension use of Leronlimab has not been halted by FDA
It has been very quiet since the end of s/c Trial enrollment. And they are talking about something, and it certainly is not talk about how to deliver the bad news
Has anything negative been announced about Leronlimab's s/c trial data?
A firm's CEO has legal disclosure obligation of information that might have a ‘material’ impact on the sponsor company's revenues.
Cytodyn is in talks regarding Leronlimab's approval, with the US, Canada and the UK.
Numerous countries are in urgent need of a drug to reduce the death rate of patients with s/c covid-19
We expect to meet our s/c Primary Endpoint at the 28 day data analysis, with reduction in death rate by 30% to about 50%.
The FDA appears willing to look at 42 day data or even 60 day data if necessary for Leronlimab to achieve Stat Significance and a p value <0.05
GSK trial reported today (SA) 40.4% death rate in placebo SOC group at 60 days.
eIND and Open Label Extension use of Leronlimab has not been halted by FDA
It has been very quiet since the end of s/c Trial enrollment. And they are talking about something, and it certainly is not talk about how to deliver the bad news
Has anything negative been announced about Leronlimab's s/c trial data?
A firm's CEO has legal disclosure obligation of information that might have a ‘material’ impact on the sponsor company's revenues.
Cytodyn is in talks regarding Leronlimab's approval, with the US, Canada and the UK.
Numerous countries are in urgent need of a drug to reduce the death rate of patients with s/c covid-19
We expect to meet our s/c Primary Endpoint at the 28 day data analysis, with reduction in death rate by 30% to about 50%.
The FDA appears willing to look at 42 day data or even 60 day data if necessary for Leronlimab to achieve Stat Significance and a p value <0.05
GSK trial reported today (SA) 40.4% death rate in placebo SOC group at 60 days.
10
